Expert oncologists discuss the VELIA study and the new frontline PARP inhibitor treatment veliparib.
A discussion of the PAOLO-1 trial regimen and the rationale behind combining olaparib and bevacizumab as post-chemotherapy maintenance.
Maurie Markman, MD, leads a discussion on the design and results of the PRIMA trial, and how it has impacted practice.
Expert panelists conclude their discussion with parting advice on the management of opioid-induced constipation.
Key opinion leaders discuss the importance of HRD testing, with special consideration of tissue testing versus somatic testing.
Turning toward the future management of opioid-induced constipation, the panel defined unmet needs and potential evolutions in care.
A discussion on how to bring awareness to clinicians that are not aware of the role of an oncology pharmacist.
Comprehensive insight regarding the cost and timing of peripherally acting mu-opioid receptor antagonist therapy in opioid-induced constipation.
Annette Hood, PharmD, BCACP, leads a discussion on the role of oncology pharmacists in supporting oncologists to determine the appropriate treatment plan for individuals with ovarian cancer.
Given the 3 available peripherally acting mu-opioid receptor antagonists for opioid-induced constipation, experts consider when to use a specific agent.
Considerations for the safety/efficacy profile of peripherally acting mu-opioid receptor antagonists, particularly given their administration route.
Key opinion leaders shift their attention to use of peripherally acting mu-opioid receptor antagonists in opioid-induced constipation.